SOME CAG PUBLICATIONS

Sutton DMC, Nair RC, Rock G and the Members of the CASG. Complications of plasma exchange. Transfusion 1989; 29: 124-127. (110)

Rock GA, Tricklebank GW, Kasaboski A, and the Members of the CASG. Plasma exchange in Canada. Canadian Medical Association Journal 1990; 142: 557-562. (120)

The Canadian Cooperative Multiple Sclerosis Study Group (including Rock G) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Lancet 1991; 337: 441-446. (127)

Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, and the Members of the CASG. Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine 1991; 325: 393-397. (128)

Rock GA, Herbert CA and the Members of the CASG. 10 Years of Apheresis in Canada. Transfusion Science 1992; 13: 111-112. (129)

Rock G, Tittley P, Sternbach M, Buskard N, Schroeder M. Repeat Plateletpheresis: The Effects on the Donor and the Yield. Vox Sanguinis 1992; 63: 102-106. (130)

Rock G, Shumak K, Kelton J, Blanchette V, Buskard N, Spasoff R, and the Members of the CASG. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32: 710-714. (131)

Rock GA, Herbert CA and the Members of the CASG. Therapeutic Apheresis in Canada. Journal of Clinical Apheresis 1992; 7: 47-48. (132)

Rock G, Buskard N, Leblond P, Shumak K, Sutton D, Hashemi S and the Members of the CASG. Target antigens of antiplatelet antibodies in patients with steroid resistant ITP of recent onset. International Journal of Hematology 1992; 56: 225-232. (133)

Cole E et al and the Members of the CASG (including Rock G). A Prospective Randomized Trial of Plasma Exchange as Additive Therapy in Idiopathic Crescentic Glomerulonephritis. American Journal of Kidney Diseases 1992; 20: 261-269. (134)

Rock G. The application of protein A immunoadsorption to remove platelet alloantibodies. Transfusion 1993; 33: 192-194. (135)

Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. British Journal of Haematology 1994; 88: 878-880. (137)

Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. British Journal of Haematology 1994; 88: 816-825. (138)

Shumak KH, Rock GA, Nair RC and the Canadian Apheresis Group. Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic Purpura. Annals of Internal Medicine 1995;122: 569-572. (140)

Rock G, Shumak K, Sutton D, Buskard N, Nair R and Members of the CAG. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. British Journal of Haematology 1996; 94: 383-386. (142)

Rock G, Buskard NA. Therapeutic plasmapheresis. Current Opinion in Hematology 1996; 3(6): 504-510. (143)

Rock G. The varying faces of thrombotic thrombocytopenic purpura. Annals of Internal Medicine 1997; 148: 343-345. (146)

Rock G, Sutton DMC. Apheresis: man versus machine. Transfusion 1997; 37: 993-994. (147)

Rock G, Sutton DMC, Freedman J, Nair RC and the members of the CAG. Pentastarch Instead of Albumin as Replacement Fluid for Therapeutic Plasma Exchange. Journal of Clinical Apheresis 1997; 12: 165-169. (148)

Leblond PF, Rock G, Herbert CA and the members of the CAG. The use of plasma as a replacement fluid for plasma exchange. Transfusion 1998; 38: 834-838 (151)

Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DMC and members of the CAG. Laboratory abnormalities in thrombotic thrombocytopenic purpura. British Journal of Haematology 1998; 103: 1031-1036. (152)

Buskard N, Rock G, Nair R, and members of the CAG. The Canadian Experience Using Plasma Exchange for Immune Thrombocytopenic Purpura. Transfusion Science 1998; 19(3): 295-300. (153)

Rock, G. and members of the CAG. Influence of Replacement Fluid on TTP: The Experience of the Canadian Apheresis Group. Transfusion Science 1998; 19(3): 199-200. (154)

Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM. Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group. Annals Int Med 1999; 131: 453-462. (158)

Rock G, Herbert C and members of the CAG. The Canadian Apheresis Group and therapeutic plasma exchange. Transfusion Science 1999; 20: 145-150. (159)

Wright J, Wang H, Hornstein A, Hogarth M, Mody M, Garvey M, Blanchette V, Rock G, Freedman J. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology 1999; 107: 546-555. (160)

Benny WB, Sutton DMC, Oger J, Bril V, McAteer MJ, Rock G. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients. Transfusion 1999; 39: 682-687. (161)

Nagpal S, Anderson D, Benstead T, Shumak K, Rock G. Treatment of Guillain-Barré Syndrome: a Cost-Effectiveness Analysis. Journal of Clinical Apheresis 1999; 14: 107-113. (162)

Rock G, Chin-Yee I, Cantin G, Giulivi A, Gluck S, Keating A, Keeny M, Klassen J, Sutherland R, and the Canadian Apheresis Group and Canadian Bone Marrow Transplant Group. Quality assurance of progenitor cell content of apheresis products: a comparison of clonogenic assays and CD34+ enumeration. Transfusion Medicine 2000; 21: 67-75. (164)

Tsai H-M, Anping L, Rock G. Inhibitors of von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura. Clinical Laboratory 2001; 47: 387-392. (175)

Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim AP, Sackett DL. Effect of Awareness of a Randomised Controlled Trial on Use of Experimental Therapy. JAMA 2003; 290(10): 1351-1355. (180)

Rivard GE, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9(6): 711-716. (181)

Rock G, Clark B, Sutton D, Members of CAG and CAAN. The Canadian apheresis registry. Transfusion and Apheresis Science 2003; 29(2): 167-177. (183)

Rock, G., Anderson, D., Clark, W., Leblond, P., Palmer, D., Sternbach, M., Sutton, D., Wells, G., Members of the CAG and members of the Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. British Journal of Haematology 2005; 129: 79-86. (188)

Clark W, Stewart K, Rock G, Sternbach M, Sutton D, Barrett B, Heidenheim P, Garg A, Churchill D, and the Canadian Apheresis Group. Plasma exchange when Myeloma presents as acute renal failure: a randomized, controlled trial. Annals of Internal Medicine Dec 2005; 143 (11):777-784. (189)

Wyllie B.F, Garg A.X, Macnab J, Rock G.A, Clark W.F and Members of the Canadian Apheresis Group. Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS): A New Index Predicting Response to Plasma Exchange. British Journal of Haematology Jan 2006;132 (2): 204-209. (194)

Foley S, Webert K, Arnold D, Rock G, Clark W, Barth D, Sutton D and members of the Canadian Apheresis Group. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney International, February 2009, 75 (112) S55-S58 (207)

Cataland SR., Peyvandi F., Mannucci PM., Lammle B., Kremer Hovinga JA., Machin SJ., Scully M., Rock G., Gilbert JC.Yang S. Wu H., Jilma B., Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, Volume 87, Issue 4, April 2012, pages 430–432 (213)

Bennett CL., Jacob, S., Dunn, BL., Georgantopoulos, P., Zheng, XL., Kwaan, HC., McKoy, JM., Magwood, JS., Qureshi, ZP., Bandarenko, N., Winters, JL., Raife, TJ., Carey, PM., Sarode, R., Kiss, JE., Damnielson, C., Ortel, TL, Clark, WF., Ablin, RJ., Rock G., Matsumoto, M., Fujimura, Y. Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Br J Haematol. June 2013; 161(6):896-8. (214)

Rock GA., Clark WF., Anderson D., Barrett B., Sutton D., Leblond P., Sternbach M., Sontrop J. and Members of the CAG. ADAMTS-13 May Not Predict Disease or Outcome in Patients with Thrombotic Thrombocytopenic Purpura. Thromb Res. 2013, 131(4). (215)

Dahlan R., McCormick B., Alkhattabi M., Gallo K., Clark W. F., Rock G. Patients’ quality of life after stopping plasma exchange: A pilot study. Transfusion and Apheresis Science, October 2014, Issue 51, pages 137–140. (217)

Clark, WF., Rock, G., Foley, R., Barth, David; Webert, K., Yenson, P., Kelton, J., Li, L. A Phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory TTP treated with Rituximab. Br J Haematol., 2015 Jul;170(2):208-17. (219)

Patriquin, C. J., Clark, W. F., Pavenski K., Arnold D.M., Rock G., Foley S. R., for the Canadian Apheresis Group. How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey; Journal of Clinical Apheresis. [Epub: 31 July 2016]. (221)

X.Long Zheng, S. Vesely, S. Cataland, P. Coppo, B. Geldziler, A. Iorio, M. Matsumoto, R. Mustafa, M. Pai, G. Rock, L. Russell, R. Tarawneh, J. Valdes, Good Practice Statements (GPS) for the Clinical Care of Patients with Thrombotic Thrombocytopenic Purpura, Journal of Thrombosis and Haemostasis, July 10, 2020. (222)